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Introduction
Many resource-poor countries with HIV 
epidemics are scaling up antiretroviral 
therapy (ART). By December 2005, an 
estimated 1.3 million people from low- 
and middle-income countries had been 
placed on treatment; 810 000 of these 
were in sub-Saharan Africa.1 Treatment 
outcomes reported from various clinics 
in sub-Saharan Africa, Haiti, Asia and 
South America have been good, compa-
rable with those observed in countries 
with higher incomes.2–7 Patient outcomes 
are usually categorized as patients alive 
and on treatment, stopped treatment, 
transferred to another facility, dead or 
“lost to follow-up”. Depending on the 
facility, patients are classified as lost to 
follow-up if they have missed two or 
more consecutive clinic appointments2 
Problem In many resource-poor countries that are scaling up antiretroviral therapy (ART), 5–25% of patients are reported as “lost 
to follow-up”. This figure is 9% in Malawi. There is no published information about the true outcome status of these patients.
Approach In four facilities in northern Malawi, ART registers and master cards were used to identify patients who had not attended 
the facility for 3 months or more and were thus registered as “lost to follow-up”. Clinic staff attempted to trace these patients and 
ascertain their true outcome status.
Local setting Of 253 patients identified as “lost to follow-up”, 127 (50%) were dead, 58% of these having died within 3 months 
of their last clinic visit. Of the 58 patients (23%) found to be alive, 21 were still receiving ART and 37 had stopped treatment (high 
transport costs being the main reason for 13 patients). Sixty-eight patients (27%) could not be traced, most commonly because 
of an incorrect address in the register. Fewer patients were alive and more patients could not be traced from the central hospital 
compared with the peripheral hospitals.
Relevant changes Better documentation of patients’ addresses and prompt follow-up of patients who are late for their appointments 
are required.
Lessons learned ART clinics in resource-poor countries should ensure that patients’ addresses are correct and comprehensive. 
Clinics should also undertake contact tracing as soon as possible in the event of non-attendance, consider facilitating access to ART 
clinics and take loss to follow-up into consideration when assessing death rates.
Bulletin of the World Health Organization 2007;85:550–554.
Une traduction en français de ce résumé figure à la fin de l’article. Al final del artículo se facilita una traducción al español.
True outcomes for patients on antiretroviral therapy who 
are “lost to follow-up” in Malawi
Joseph Kwong-Leung Yu,a,b Solomon Chih-Cheng Chen,b Kuo-Yang Wang,b Chao-Sung Chang,b  
Simon D Makombe,c Erik J Schouten c & Anthony D Harries c
.ةلاقلما هذهل لماكلا صنلا ةياهن في ةصلاخلا هذهل ةيبرعلا ةمجترلا
Lessons from the field
a  Taiwan Medical Mission to Malawi, Mzuzu Central Hospital, Mzuzu, Malawi.
b  International Medical Cooperation and Development Center, Pingtung Christian Hospital, Pingtung, Taiwan, China.
c  Clinical HIV Unit, Ministry of Health, PO Box 30377, Lilongwe, Malawi. Correspondence to Anthony D Harries (e-mail adharries@malawi.net).
doi: 10.2471/BLT.06.037739
(Submitted: 17 October 2006 – Final revised version received: 1 February 2007 – Accepted: 2 February 2007)
or have not been seen for at least 2 or 3 
months.4–6 The proportion of patients 
lost to follow-up differs between clinics, 
ranging from 5% in programmes sup-
ported by Médecins Sans Frontières5 
to 25% in western Kenya.4 In 18 ART-
delivery programmes in Africa, Asia and 
South America, 15% of 4810 patients 
were lost to follow-up in the first year 
of ART, with the average being 12% in 
programmes with active follow-up and 
19% in those with no active follow-up.7 
To our knowledge, there are no pub-
lished data from resource-poor coun-
tries on the true outcome status of these 
patients.
Malawi – a small resource-poor 
country in southern Africa – has been 
engaged in ART scale-up for nearly 3 
years. By 31 March 2006, 46 702 pa-
tients had ever started receiving ART 
in 66 facilities in the public sector; of 
these, 33 891 (73%) were registered as 
alive, 5131 (11%) were dead, 4226 (9%) 
were lost to follow-up, 3140 (7%) had 
transferred to another facility and 314 
(1%) had stopped therapy.8 We hypoth-
esized that many patients lost to follow-up 
may have died, and therefore conducted a 
study in northern Malawi to investigate 
this problem.
Methods
Details on the delivery and monitoring 
of ART in Malawi have been described 
previously.9 When patients start ART, 
their details are entered on master cards 
and an ART register. Patients attend 
the ART clinic each month, at which 
time their outcome status is entered 
on the master card and they are given 
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another month’s supply of ART drugs. 
If a patient is not seen in the clinic for 
three consecutive months, the patient is 
registered as a “defaulter” (an abbrevi-
ated term for “lost to follow-up”) on the 
master card and also on the register.
Four public-sector ART facilities 
in the northern region of Malawi were 
selected for the study. These included 
one central hospital and three peripheral 
hospitals (two district hospitals and one 
mission hospital). Provision of free ART 
was initiated at the central and mission 
hospitals in July 2004, and at the two 
district hospitals in January and June 
2005 respectively. For the period be-
tween the date when each facility started 
to provide free ART and 31 March 2006, 
we identified all patients indicated on the 
master cards and registers as a defaulter. 
Using contact details, ART facility staff 
visited the patients’ homes to try to ascer-
tain their true outcome status. If patients 
were traced to the home, they were asked 
whether they were still taking ART and 
if not, why they had stopped. If the pa-
tient had died, the relatives were asked 
when the patient had died. If the patient 
had moved away, relatives or friends 
were asked when they had moved.
Ethical approval for the study was 
granted by the Malawi National Health 
Sciences Research Committee. Informed 
consent was obtained from patients be-
ing interviewed, and staff took care not 
to disclose that the patient was receiv-
ing ART when interviewing relatives 
or friends in the event of the patient’s 
death or transfer.
Data were collected on structured 
forms, and analysis was carried out us-
ing Epi Info version 6.0. Patients from 
the central and the peripheral hospitals 
were compared: the c² test with relative 
risks (RR) and 95% confidence intervals 
(CI) were used for characteristics and 
outcomes, and the student’s t-test was 
used for time periods between start of 
ART, default and patient tracing, with 
differences at the level of 0.05 being 
regarded as significant.
Results
During the period of observation, 5009 
patients were registered as ever hav-
ing started ART in the four hospitals. 
Of these, 253 (5%) were registered as 
defaulters. Table 1 shows patient char-
acteristics, reasons for starting ART, 
treatment regimens, results of defaulter 
tracing and time periods between start 
of ART, date of default and date of pa-
tient tracing.
For all defaulters, the median time 
between start of ART and date of default 
was 4.3 months, and between date of 
Table 1.  Characteristics and true outcome status of patients on ART who were classified as “lost to follow-up” from four 
hospitals in Malawi
Characteristics and outcome status All hospitals Central hospital Three peripheral  
hospitals
Number of patients ever started on ART 5009 3158 1851
Female patients 2985 (60%) 1854 (59%) 1131 (61%)
Children (aged < 15 years) 403 (8%) 371 (12%) 32 (2%)
Number of patients who defaulted 253 (5%) 126 (4%) 127 (7%)
Median (range) time between starting ART and diagnosis of 
default in months
4.3
(2.6–24.6)
3.7
(2.9–19.5)
4.5
(2.6–24.6)
Median (range) time between diagnosis of default and home 
visits in months
6.4
(0.1–18.3)
8.2
(0.1–18.3)
5.1
(0.1–15.6)
Characteristics of defaulting patients:
Median age (years) 35 35 35
Female patients 151 (60%) 67 (53%) 84 (66%)
Children (aged < 15 years) 6 (2%) 4 (3%) 2 (2%)
Indication for ART:
WHO clinical stage 3 172 (68%) 87 (69%) 85 (67%)
WHO clinical stage 4 72 (28%) 31 (25%) 41 (32%)
WHO clinical stage 1 or 2 with a CD4 count < 250 per mm³ 9 (4%) 8 (6%) 1 (1%)
ART regimen:
First-line regimena 250 (99%) 124 (98%) 126 (99%)
Alternative first-line regimenb 3 (1%) 2 (2%) 1 (1%)
default and home visits was 6.4 months. 
Overall, the commonest reason for de-
fault was death, this being the case for 
50% of patients. Of those who died, 
57% died within 3 months of their last 
clinic attendance, the median time be-
tween start of ART and death being 2.9 
(range, 0.1–19.2) months. Fifty-eight 
(23%) patients were still alive; about 
one-third had transferred themselves to 
another ART clinic without informing 
the clinic where they were registered and 
about two-thirds had stopped therapy. 
Of the patients who had stopped ART, 
reasons included the high cost of trans-
port to the clinic (13 patients; 35%), re-
ligious beliefs (4 patients; 11%), persua-
sion by relatives to stop ART (4 patients; 
11%) and other reasons (16 patients; 
43%). The remaining 68 patients (27%) 
could not be traced, most frequently 
because of an incorrect address in the 
ART register. The median time between 
default and home visits was 1.8 (range, 
0.1–16) months for patients who were 
found to be still alive and 4.8 (range, 
0.1–18.3) months for patients who 
could not be traced, a highly significant 
difference (P < 0.001).
The characteristics of patients from 
the central and peripheral hospitals 
were similar, except that there were 
significantly more female defaulters in 
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Characteristics and outcome status All hospitals Central hospital Three peripheral  
hospitals
True outcome status at the default tracing visit:
Total alive 58 (23%) 18 (14%) 40 (32%)
Status of patients found to be alive:
Alive on ART at the same clinicc 1 (2%) 0 (0%) 1 (3%)
Alive on ART at a different clinicd 20 (34%) 9 (50%) 11 (28%)
Alive but had stopped ART 37 (64%) 9 (50%) 28 (69%)
Dead 127 (50%) 58 (46%) 69 (54%)
Time of death after last ART attendance:
Month 1 30 (24%) 15 (26%) 15 (22%)
Month 2 29 (23%) 15 (26%) 14 (20%)
Month 3 14 (11%) 5 (9%) 9 (13%)
Month 4 and beyond 54 (42%) 23 (39%) 31 (45%)
Lost to follow-up 68 (27%) 50 (40%) 18 (14%)
Reasons for unsuccessful tracing:
Incorrect address in ART register 55 (81%) 42 (84%) 13 (72%)
Patient moved and family remained 7 (10%) 4 (8%) 3 (17%)
Patient and family moved 6 (9%) 4 (8%) 2 (11%)
ART, antiretroviral therapy.
a  Fixed drug combination of stavudine, lamivudine and nevirapine.
b  Drug regimen where zidovudine is substituted for stavudine in case of peripheral neuropathy, or efavirenz for nevirapine in case of hepatitis or severe cutaneous 
reaction.
c  Patient came late for appointment and did not disclose to ART clinic staff that he/she was already registered for treatment.
d  Patients transferred to other ART clinics without informing the staff from the clinic where they had first been registered.
(Table 1, cont.)
Box 1. Lessons learned
•  An operational research study in northern Malawi found that the reasons for being “lost 
to follow-up” for patients started on antiretroviral therapy (ART) were: death, 50%; alive 
and on ART, mainly at another clinic, 8%; alive and stopped therapy, 15%; and unable to be 
traced, 27%. The commonest reason for remaining patients being “lost to follow-up” was an 
incorrect address in the ART register.
•  ART clinics need to record correct and comprehensive addresses, and should try to do 
contact tracing as soon as possible in the event of clinic non-attendance. Clinics also should 
consider facilitating better access to care for those with transport difficulties.
• True outcome status may differ depending on whether the ART clinic is in an urban or rural 
environment.
• In any comparison of treatment outcomes between clinics, particularly with regard to death 
rates, the issue of patient loss to follow-up cannot be ignored.
peripheral than in central hospitals (P < 
0.05). The time between default and 
home visits was significantly longer for 
patients from central hospitals than for 
patients from peripheral hospitals (P < 
0.001). Significantly fewer patients from 
central hospitals were found alive (RR, 
0.45; 95% CI, 0.28–0.75; P < 0.01) and 
significantly more patients from central 
hospitals could not be traced (RR, 2.80; 
95% CI, 1.7–4.1; P < 0.001) compared 
with patients from peripheral hospitals. 
There were no significant differences 
in the reasons for stopping ART or for 
continued loss to follow-up between the 
two groups.
Discussion
This study shows that half of the pa-
tients receiving ART who were subse-
quently lost to follow-up were dead, with 
a large proportion dying soon after they 
failed to attend the clinic. The reasons 
for death were not ascertained. About 
one-quarter of patients were alive, some 
having transferred to another facility 
and some deciding to stop therapy. An 
important reason for stopping therapy 
was the cost of transport from homes 
to clinics. The remaining patients could 
not be traced, with an incorrect address 
in the register being the most common 
reason. Whether patients gave a wrong 
address or whether the details obtained 
by clinic staff were insufficient is unclear. 
These overall outcomes are similar in 
many respects to those found several 
years ago in Malawi in a study in pa-
tients registered as defaulters with regard 
to treatment for tuberculosis.10
There were some differences be-
tween the central and peripheral hospi-
tals in terms of the characteristics of de-
faulters. A higher proportion of women 
from the peripheral hospitals were 
defaulters. Although part of the explana-
tion may be that peripheral hospitals reg-
istered slightly more women to receive 
ART, other factors may be responsible 
and this requires further study. The rate 
of failure to trace patients was higher for 
patients from the central hospital, and 
this may relate to the longer period of 
time between default and the home visit 
and the general difficulties faced in trac-
ing mobile patients in a congested urban 
environment.
There are several important lessons 
to be learnt from this study (Box 1). 
First, ART clinics need to ensure that 
the address recorded for the patient is 
correct in order to facilitate contact trac-
ing if this becomes necessary. Second, 
provided that resources are available, 
clinics should attempt to trace patients 
who stop attending the clinic in order 
to bring patients back to therapy. This 
needs to be done as soon as possible, 
as the longer the delay the more likely 
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Résumé
Véritables issues du traitement antirétroviral pour les patients considérés comme « perdus de vue »  
au Malawi
Problématique Dans nombre de pays à revenu modeste qui 
ont entrepris d’étendre le traitement antirétroviral (ART), 5 à 25 % 
des patients sont signalés comme « perdus de vue ». Ce chiffre est 
de 9 % pour le Malawi. On ne dispose pas de données publiées 
sur la véritable issue pour ces patients.
Démarche Dans quatre établissements de la partie nord du 
Malawi, on a utilisé les livres-registres de délivrance des ART 
et les cartes maîtresses pour identifier les patients ne s’étant pas 
rendu dans l’établissement depuis 3 mois ou plus et enregistrés 
ainsi comme « perdus de vue ».  Le personnel clinique s’est attaché 
à retrouver la trace de ces patients et à déterminer l’issue véritable 
du traitement dans leur cas.
Contexte local Sur 253 patients classés comme « perdus de 
vue », 127 (50 %) étaient morts et parmi ces patients décédés, 
58 % avaient perdu la vie dans les 3 mois suivant leur dernière 
visite au dispensaire. Parmi les 58 patients retrouvés en vie 
(23 %), 21 prenaient encore des antirétroviraux et 37 avaient 
interrompu leur traitement (les coûts excessif du transport étant la 
principale raison de cet arrêt pour 13 d’entre eux). Soixante-huit 
patients (27 %) n’on pu être retrouvés, le plus souvent à cause 
de l’inexactitude de l’adresse enregistrée dans leur dossier. Peu 
des patients perdus de vue étaient encore en vie et le nombre des 
patients impossibles à retrouver était plus important pour l’hôpital 
central que pour les établissements périphériques.
Modifications pertinentes Il convient de relever avec plus de 
rigueur l’adresse des patients et d’entreprendre rapidement un 
suivi de ceux qui tardent à se présenter aux rendez-vous.
Enseignements tirés Les établissements délivrant les 
traitements ART dans les pays à faible revenu doivent s’assurer de 
l’exactitude et de la complétude de l’adresse qu’ils enregistrent 
pour leurs patients. Ils doivent aussi entreprendre dès que possible 
une recherche des contacts si un patient ne se présente plus aux 
rendez-vous, envisager de faciliter l’accès au lieu de délivrance du 
traitement ART et prendre en compte les « perdus de vue » dans 
l’évaluation des taux de mortalité.
Problema En muchos países con recursos escasos que están 
extendiendo masivamente la terapia antirretroviral (TAR) se 
informa de que un 5%-25% de los pacientes tratados se pierde 
en el seguimiento. En Malawi el porcentaje es del 9%. No 
hay datos publicados sobre la verdadera evolución de esos 
pacientes.
Métodos En cuatro establecimientos del norte de Malawi, 
se utilizaron los registros de TAR y las tarjetas maestras para 
identificar a los pacientes que no habían acudido al establecimiento 
durante 3 o más meses y estaban registrados por tanto como 
«perdidos en el seguimiento». Trabajadores de esos centros 
intentaron localizar a los pacientes y evaluar su estado de salud 
real.
Contexto local De 253 pacientes identificados como «perdidos 
en el seguimiento», 127 (50%) habían muerto, el 58% de ellos 
en los 3 meses siguientes a su última visita al consultorio. De los 
58 pacientes (23%) hallados con vida, 21 seguían recibiendo 
TAR y 37 habían interrumpido el tratamiento (13 de ellos 
Resumen
Evolución real de los pacientes sometidos a terapia antirretroviral y perdidos en el seguimiento en Malawi
adujeron como causa principal el alto precio de los transportes). 
Sesenta y ocho pacientes (27%) no pudieron ser localizados, 
fundamentalmente porque en los registros figuraba una dirección 
incorrecta. En comparación con los hospitales periféricos, en el 
caso del hospital central había menos pacientes vivos y más a los 
que no se pudo localizar.
Cambios destacables Es necesario registrar mejor las 
direcciones de los pacientes y reanudar rápidamente el seguimiento 
de los que falten a las citas concertadas.
Enseñanzas resultantes Los consultorios de TAR de los países 
de recursos escasos deben procurar que las direcciones de 
sus pacientes se registren correctamente y  sin omisiones. Los 
consultorios deben adoptar además lo antes posible medidas de 
localización de contactos en caso de no asistencia, estudiar la 
manera de facilitar el acceso a los consultorios de TAR, y tener 
en cuenta las pérdidas en el seguimiento a la hora de evaluar las 
tasas de mortalidad.
it is that the patient will be untrace-
able. Third, ART programmes need to 
consider the plight of those who have 
difficulty accessing ART clinics, and 
either try to site new ART clinics in bet-
ter locations, set up outreach clinics or 
look into ways of financially supporting 
patients’ transport to clinics. Fourth, 
there may be differences in outcomes 
between patients who have defaulted 
from central urban hospitals compared 
with those from more peripheral rural 
hospitals, and ART programmes should 
determine local causes of loss to follow-
up. Finally, country and clinic reports 
on treatment outcomes must take the 
issue of loss to follow-up into consider-
ation, particularly with regard to death 
rates.  O
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صخلم
 ةجلاعلما في ةعباتلما نع ينعطقنلما ضىرملل يقيقحلا لآلما
يولاام في ةيرقهقلا تاسويرفلل ةداضلما ةيودلأاب
 ةداضلما  ةجلاعلماب  ضهنت  يتلا  دراولماب  ةيرقفلا  نادلبلا  مظعم  في  :ةلكشلما
 تعطقنا  دق  ضىرلما  نم %22-5  نأ  ريراقتلا  في دري  ،ةيرقهقلا  تاسويرفلل
 نع ةروشنم تامولعم دجوي لاو .%9  ءلاؤه لّكشي يولاام فيو .مهتعباتم
.ضىرلما ءلاؤهل يقيقحلا لآلما
 فُّرعتلل تاقاطبلاو تلاجسلا مدختست ،يولاام لماش عقت قفارم 4 في :بولسلأا
 نول َّجَسُيو ،ثركأ وأ روهش 3 ةدلم يحصلا قفرلما نوروزي لا نيذلا ضىرلما لىع
 ءافتقا نويريسرلا نولماعلا لواحيو .ةعباتلما نع ينعطقنلما نم كلذل ةجيتن
.يقيقحلا مهلآمو مهعاضوأ لىع فُّرعتلاو ضىرلما ءلاؤه رثأ
 تام دق هنأو ،ًاضيرم 253 ةعباتلما نع ينعطقنلما ددع نأ َّينبت :ليحلما عقولما
 ةثلاثلا  رهشلأا للاخ اوتام تىولما  ءلاؤه نم %58  نأو ،)%50(  127  مهنم
 ،ءايحأ نولازيلا )%23( ًاضيرم 58 نأ دجو مايف .ةيرخلأا مهترايز تلت يتلا
 ،ةيرقهقلا تاسويرفلل ةداضلما ةيودلأاب ةجلاعلما ى َّقلتي لازيلا مهنم 21 نأو
 لقنلا لئاسول ةعفترلما فيلاكتلا تناك دقو( ةجلاعلما مهنم 37 فقوأ مايف
 68  رثأ  ءافتقا  نكيم لمو .)مهنم  ًاضيرم 13  دنع كلذل سييئرلا  ببسلا يه
 في ل َّجسلما ناونعلا ةحص مدع وه كلذل ًاعويش بابسلأا ثركأو ،)%27( ًاضيرم
 ةبسنلاب لقأ ةيزكرلما تايفشتسلما في ددعلا نأ ودبيو .تاقاطبلاو تلاجسلا
 هرثأ ءافتقا ر َّذعت نلم ةبسنلاب ثركأ هنأو ،ةايحلا ديق لىع اوقب نيذلا ضىرملل
.ةيطيحلما تايفشتسلما في هيلع وه ام عم ةنراقلماب
 رْوَف  مهتعباتمو  ضىرلما  نيوانع  قيثوت  ينسحت  يغبني  :ةئملالما  تايرـيغتلا
.مهديعاوم في روضحلا نع مهرخأت
 تاسويرفلل ةداضلما ةيودلأاب ةجلاعلما تادايع لىع يغبني :ةدافتسلما سوردلا
 نأ  يغبنيو  .اهيدل  ضىرملل  ةافوتسمو  ةحيحص  نيوانع  ليجست  ةيرقهقلا
 ةحاتلإ  ليهستلا  ى َّخوتـت  نأو  ،روضحلا  نع  مهبُّيغت  رْوَف  ضىرلما  رثأ  يفتقت
 ،كلذل ةص َّصخلما تادايعلا في ةيرقهقلا تاسويرفلل ةداضلما ةيودلأاب ةجلاعلما
.تايفولا تلادعم ميـيقت دنع نابسحلا في ةعباتلما نادقف ذخأ عم
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